Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows